Author Archives: admin


Link between cells associated with aging and bone loss – Medical Xpress

August 21, 2017 Osteoblasts actively synthesizing osteoid. Credit: Robert M. Hunt; Wikipedia.

Mayo Clinic researchers have reported a causal link between senescent cells - the cells associated with aging and age-related disease - and bone loss in mice. Targeting these cells led to an increase in bone mass and strength. The findings appear online in Nature Medicine.

Low bone mass and osteoporosis are estimated to be a major public health threat for almost 44 million U.S. women and men 50 and older, according to the National Osteoporosis Foundation. Bone is a living tissue that is constantly being broken down and replaced. Osteoporosis occurs when the creation of new bone doesn't keep up with the removal of old bone.

"While we know from previous work that the accumulation of senescent cells causes tissue dysfunction, the role of cell senescence in osteoporosis up to this point has been unclear," says Sundeep Khosla, M.D., director of the Aging Bone and Muscle program at Mayo Clinic's Robert and Arlene Kogod Center on Aging. "The novelty of this work for the bone field lies in the fact that, rather than targeting a bone-specific pathway, as is the case for all current treatments for osteoporosis, we targeted a fundamental aging process that has the potential to improve not only bone mass, but also alleviate other age-related conditions as a group."

In the study, researchers used multiple approaches to target senescent cells in mice with established bone loss between 20 and 22 months of age. That's the equivalent of over age 70 in humans. Approaches included using:

"The effects of all three approaches on aging bone were strikingly similar," says Dr. Khosla. "They all enhanced bone mass and strength by reducing bone resorption but maintaining or increasing bone formation, which is fundamentally different from all current osteoporosis drugs."

The benefits on bone found in elderly mice were not evident in younger mice. That, coupled with the finding that the senolytic drugs were effective when given only intermittently, supports the link between senescent cells and age-related bone loss. Researchers administered a senolytic drug combination (dasatinib and quercetin) once per month to eliminate senescent cells.

"Even though this senolytic drug combination was only present in the mice for a couple of hours, it eliminated senescent cells and had a long-lasting effect," says James Kirkland, M.D., Ph.D., director of the Kogod Center on Aging and co-corresponding author of the study. "This is another piece of the mounting evidence that senolytic drugs are targeting basic aging processes and could have widespread application in treating multiple chronic diseases."

Drs. Kirkland and Khosla say that being able to administer the drugs intermittently poses less risk for side effects than with drugs that must be taken daily. Also, current therapeutics in the bone field that treat bone loss "work against themselves," meaning that, if they decrease resorption, they also decrease formation. In this study, the senolytic drugs decreased bone resorption, while maintaining or increasing bone formation.

"With the aging of the population in the U.S. and around the world, age-related bone loss is going to continue to be an enormous public health problem, and patients with osteoporosis have a higher risk for other age-related comorbidities," says Dr. Khosla. "By combining the knowledge of three separate labs and enlisting the expertise of several others in a true team science approach, we were able to collaborate and make these findings possible. We need to continue to pursue these potential interventions that target fundamental aging mechanisms as, hopefully, an eventual way to reduce the burden of fractures and other conditions, such as cardiovascular dysfunction, diabetes and frailty."

Explore further: Researchers uncover new agents

More information: Targeting cellular senescence prevents age-related bone loss in mice, Nature Medicine (2017). DOI: 10.1038/nm.4385

Journal reference: Nature Medicine

Provided by: Mayo Clinic

Mayo Clinic researchers have uncovered three new agents to add to the emerging repertoire of drugs that aim to delay the onset of aging by targeting senescent cells - cells that contribute to frailty and other age-related ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See more here:
Link between cells associated with aging and bone loss - Medical Xpress

Study sheds light on why some breast cancers have limited response to immunotherapy – Medical Xpress

August 21, 2017 Jonathan Serody, M.D., UNC Lineberger member and the Elizabeth Thomas Professor in the UNC School of Medicine, is first author of a study that investigated why drugs that are designed to unleash the immune system against cancer were ineffective in a type of triple negative breast cancer with a heavy presence of immune cells. Credit: Brian Strickland/UNC Lineberger

UNC Lineberger Comprehensive Cancer Center researchers have identified a possible reason why some aggressive breast cancers are unresponsive to certain immunotherapy treatments, as well as a potential solution.

In the Journal of Clinical Investigation, researchers report on their study that explored a perplexing question: Why were drugs designed to unleash the immune system against cancer ineffective in a type of triple negative breast cancer with a heavy presence of immune cells? Their findings could lead to a strategy to improve immunotherapy responses in the "claudin-low" subtype of breast cancer.

"We were trying to figure out why a tumor made up, in some instances, of half immune cells doesn't respond to a treatment that should ramp up immune cells present in the tumor," said the study's senior author Jonathan Serody, MD, UNC Lineberger member and the Elizabeth Thomas Professor in the UNC School of Medicine. "I think it's important for us to try to start segregating out the types of tumors that don't respond to these treatments at a much granular genomic level, and try to figure out new mechanisms to enhance the response rate to immunotherapy."

The American Cancer Society estimates that approximately 12 percent of breast cancers are "triple negative," meaning they lack three cell surface receptors that are known to help drive the cancer. Triple negative breast cancer tumors typically grow faster and come back sooner than other breast cancer types. There are no targeted treatments for these cancers.

In a subset of triple negative breast cancers known as "claudin low," researchers found an elevated level of immune cells in and around the tumors. They believed this would help the body fight the cancer. However, the researchers found the opposite: "Checkpoint inhibitors," a type of immunotherapy that works by unlocking the immune system's brakes against cancer, were ineffective in this subtype.

They determined with gene expression analysis that, instead of being flooded with immune cells that attack cancer tumors, claudin-low tumors had a high concentration of regulatory T-cells - a type of immune cell that suppresses the body's defenses. Claudin-low tumors were releasing a chemical signal to attract these regulatory T-cells.

"This regulatory T-cell population is preventing the immune system from rejecting the cancer," said UNC Lineberger's Benjamin Vincent, MD, an assistant professor in the UNC School of Medicine. "We thought if we could get rid of those cells, we could help the immune system better fight the breast cancer cells."

In an effort to allow the immune-stimulating cancer treatments to work, the researchers tested an investigational approach to deplete the regulatory T-cells, and they combined the treatment with a checkpoint inhibitor in order to try to improve outcomes. This combination slowed tumor growth. They believe they have identified a key aspect of what is preventing immunotherapy treatments from working.

"This finding may shed some light on why response rates to immunotherapy treatments remain low in triple negative breast cancer," Vincent said. "We are looking to understand why patients who don't respond don't respond, and what we can do to render their tumors immunotherapy responsive."

Vincent is helping to lead a clinical trial testing this strategy to improve responses to checkpoint inhibitors. Researchers also believe these findings may also underscore the need to study other cancer types at a genomic level to understand differences in response rates to immunotherapy treatments.

"This speaks to the mission of UNC Lineberger, which is to conduct groundbreaking basic science research, but always with the mission of extending and improving the lives of patients as our end goal," Vincent said.

Explore further: A molecular subtype of bladder cancer resembles breast cancer

More information: Nicholas A. Taylor et al, Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer, Journal of Clinical Investigation (2017). DOI: 10.1172/JCI90499

Journal reference: Journal of Clinical Investigation

Provided by: UNC Lineberger Comprehensive Cancer Center

Adjust slider to filter visible comments by rank

Display comments: newest first

To get a quick cure of Herpes Simplex Virus, ALS, Cancer, Hepatitis, HIV/AIDs and Other STD's contact Dr oshogum now for urgent treatment and cure. Help me within 2wweks after using Fr oshogum Remedy i got cured. I went for text and i am now HSV free. Contact Dr Oshogum today Via his Email: oshogumspelltemple@live.com

Note he also have cures to diseases like

COMPLEX PARTIAL SEIURE ANAL FISSURE VIRUS DIABETES 1/2 WEAK ERECTION HERPES HIV/AIDS PILE STROKE PREMATURE EJACULATION ERECTILE DYSFUNCTION HPV ALS CANCER/RECTUM OR PROSTRATE HEART FAILURE .

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View original post here:
Study sheds light on why some breast cancers have limited response to immunotherapy - Medical Xpress

Police: Fugitive’s death ‘breaks’ cell behind Spain attacks – Medicine Hat News

By Joseph Wilson, Aritz Parra And Lori Hinnant, The Associated Press on August 21, 2017.

SUBIRATS, Spain The lone fugitive from the Spanish cell that killed 15 people in and near Barcelona was shot to death Monday after he flashed what turned out to be a fake suicide belt at two troopers who confronted him in a vineyard not far from the city he terrorized, authorities said.

Police said they had scientific evidence that Younes Abouyaaqoub, 22, drove the van that barrelled through Barcelonas crowded Las Ramblas promenade, killing 13 people on Thursday, then hijacked a car and fatally stabbed its driver while making his getaway.

Abouyaaqoubs brother and friends made up the rest of the 12-man extremist cell, along with an imam who was one of two people killed in what police said was a botched bomb-making operation.

After four days on the run, Abouyaaqoub was spotted outside a train station west of Barcelona on Monday afternoon. A second witness told police she was certain she had seen the man whose photo has gone around the world as part of an international manhunt.

Two officers found him hiding in a nearby vineyard and asked for his identification, according to the head of the Catalan police. He was shot to death when he opened his shirt to reveal what looked to be explosives and cried out Allah is great in Arabic, regional police chief Josep Luis Trapero said.

A bomb disposal robot was dispatched to examine the downed suspect before police determined the bomb belt was not real, Trapero said. A bag full of knives was found with his body, police said.

A police photo of the body seen by The Associated Press showed his bloodied face, bearing several days stubble on the chin.

With Abouyaaqoubs death, the group responsible for last weeks fatal van attacks has now been broken, Trapero said.

The arrest of this person was the priority for the police because it closed the detention and dismantling of the group that we had identified, he said.

Four are under arrest, and eight are dead: five shot by police in the seaside town of Cambrils, where a second van attack left one pedestrian dead early Friday; two others killed on the eve of the Barcelona attack in a botched bomb-making operation; and Abouyaaqoub.

The Islamic State group has claimed responsibility for both the Cambrils and Barcelona attacks.

Roser Ventura, whose father owns a vineyard between the towns of Sadurni dAnoia and Subirats, said she alerted the regional Catalan police when they spotted a car crossing their property at high speed.

The police told us to leave the premises and go home. We heard a helicopter flying around and many police cars coming toward the gas station that is some 600 metres from the property, Ventura said.

The search for Abouyaaqoub ended on the same day that Catalan police confirmed that he was the last remaining cell member thought to still be at large and provided a timeline of his movements.

Authorities said earlier Monday they had evidence that pinpointed Abouyaaqoub as the driver of the van that plowed down the Las Ramblas promenade, killing 13 pedestrians and injuring more than 120 others.

Trapero said that after abandoning the vehicle, Abouyaaqoub walked through Barcelona for about 90 minutes, through the famed La Boqueria market and nearly to Barcelona University.

The Spanish newspaper El Pais published images Monday of what it said was Abouyaaqoub leaving the van attack site on foot. The three images show a slim man wearing sunglasses walking through La Boqueria.

In a parking lot often used by university students, he then hijacked a Ford Focus belonging to Pau Perez, stabbing Perez to death and taking the wheel with his final victims body in the backseat. Minutes later, Abouyaaqoub plowed through a police checkpoint with the stolen car and abandoned the vehicle, disappearing into the night.

The manhunt for him reached well beyond Spains borders, but in the end, Abouyaaqoub died about 30 kilometres (18 miles) from where he was last spotted.

After the carnage in Barcelona, authorities took a closer look at an explosion the night before in a house south of the city. Police initially had dismissed it as a household accident.

Along with two bodies, the more exhaustive search turned up remnants of over 100 butane gas tanks and materials needed for the TATP explosive, which has been used previously by Islamic State militants for attacks in Paris and Brussels, among others.

The equipment, along with reports that Abouyaaqoub had rented three vans, suggested the militant cell was making plans for an even more massive attack on the city.

Family and friends of the young men, nearly all with roots in Morocco, described them as well-integrated members of the community in Ripoll, a quintessentially Catalan town nestled into the foothills of the Pyrenees.

I knew everyone implicated in the attacks. These were people who avoided problems, kept their distance when they saw a fight, Saber Oukabir, a cousin of two of the attackers, said.

The group members started spending time with the imam who police think was their ideological leader about six months ago, Oukabir said. I dont know what could have happened, if he manipulated them, if he drugged them or what.

Fernando Reinares, director of the program on global terrorism at Spains Elcano Royal Institute, said imams such as Abdelbaki Es Satty have made strong inroads into the regions community of North African immigrants, often reaching their Spanish-born children.

He successfully exploited the dense, overlapping, pre-existing kinship, friendship and neighbourhood ties between these young Muslims, Reinares said in an email to The Associated Press. One of the reasons why Catalonia is the main scenario for both jihadist radicalization and involvement in the whole of Spain is certainly related to the extraordinary, unparalleled concentration in the region of Salafist congregations and imams, such as Es Satty.

Regional authorities said Monday that 48 people were still hospitalized from the attacks in Barcelona and Cambrils, eight of them in critical condition.

Catalonias regional president, meanwhile, said regional and local authorities had rejected the Spanish governments suggestion to place traffic barriers to protect the Las Ramblas promenade because they deemed them inefficient.

Carles Puigdemont told La Sexta television the barriers wouldnt have prevented vehicles from entering the promenade at other points and he said closing off Las Ramblas was impractical because emergency vehicles still needed access.

On Monday, crowds of people continued to lay flowers, candles and heart-shaped balloons at the top of the pedestrian promenade where the van struck and at other smaller tributes.

Las Ramblas also regained some normality, with throngs of people walking up and down, tourists arriving and residents going about their daily business.

We have to stand strong in front of these betrayers, assassins, terrorists, said resident Monserrat Mora. Because Barcelona is strong and they will not be able to prevail with us.

_____

Parra contributed from Madrid along with Ciaran Giles. Hinnant contributed from Barcelona. Reda Zeireg in Rabat, Morocco contributed.

You must be logged in to post a comment.

Read the original post:
Police: Fugitive's death 'breaks' cell behind Spain attacks - Medicine Hat News

Howard University Hosts ‘Be The Match’ Marrow Registry Drive – Howard Newsroom (press release)

Howard University Hospital's Dr. Ermias Aytenfisu seeks to clear up misconceptions about marrow donation in the minority community.

WASHINGTON, D.C. (August 21, 2017) Elsa Nega is an Ethiopian-Canadian mother of two young children. She loves her children and wants to watch them grow. However, Nega has a rare form of blood cancer, leukemia, and needs a bone marrow transplant to survive.

Black patients like Nega are the least likely to find their suitable blood marrow match, according to Be The Match which is hosting a Stem Cell/Bone Marrow registry event at the Howard University College of Medicine on Wednesday, Aug. 30 between 11 a.m. and 3 p.m. The exact location for the registry drive is the lobby outside of room 1008 in the Numa P. Adams building.

Negas story began in February when she walked into her local ER and was rushed to intensive care. By the next morning Nega was diagnosed with Acute Lymphoblastic Leukemia (ALL) and started on chemo immediately. Unlike 90 percent of patients who go into remission after the first round of chemo, she did not.

Now, after three rounds of chemo, a bone marrow transplant is her only hope of recovery. Negas siblings were not a match and she is reaching out to the Washington region because of its large population of people of Ethiopian descent.

There are a lot of myths associated with marrow donation, said Amanda Holk, community engagement representative with the Be The Match in Washington, D.C. There is so much fear surrounding the process but most donors are back to work the next day.

ErmiasM. Aytenfisu, M.D., stroke medical director at Howard University Hospital said the most common way to donate bone marrow is through a procedure called peripheral stem cell donation. No surgery is involved. Donors receive medication to increase peripheral stem cells before the donation. On the day of donation, blood is removed through a needle on one arm and passed through a machine that separates out the blood-forming cells. Uncommonly marrow donation involves surgical techniques that use a special needle to take out blood forming cells. During the procedure, the patient is anesthetized and feels no pain.

Joining the bone marrow registry at the Howard University College of Medicine event involves a simple as a cheek swab and an application. A persons chance of being a match at that point is only 1 in 500. But, for a patient like Elsa, you could be the only one. Elsa does not have a single match on the registry although there are 30 million people signed up.

For more information, contact Amanda Holk via email AHolk@nmdp.org or 202-875-9987

For the Howard University registry drive, please note that you must be between the ages of 18 and 44 to join the registry since research has shown that the younger the cells, the better the patient outcomes. And the following conditions prevent you from joining:

Hepatitis B or C

HIV

Organ, marrow or stem cell transplant recipient

Stroke or TIA (transient ischemic attack)

Other upcoming local events to support Elsa Nega:

*Empower the community (The Helen Show)

Date: 08/26/2017 (Sat.)

Location: Washington Convention Center

*Ethiopian Day Festival

Date: 09/03/2017 (Sun.)

Location: Downtown Silver Spring

About Howard University Hospital

Over the course of its roughly 155-year history of providing the finest primary, secondary and tertiary health care services, Howard University Hospital (HUH) remains one of the most comprehensive health care facilities in the Washington, D.C. metropolitan area and designated a DC Level 1 Trauma Center. The hospital is the nation's only teaching hospital located on the campus of a historically Black university. For more information, visit huhealthcare.com

See the original post here:
Howard University Hosts 'Be The Match' Marrow Registry Drive - Howard Newsroom (press release)

Scientists find a much faster way to classify our cells – Engadget

Here's how it works: Cells are first placed into wells, where molecular markers attach themselves to each RNA strand. The process is repeated, and eventually each cell type has a unique combination of tags on its RNA molecules. The team can then break the cells open chemically and read back the sequences of tags. "We came up with this scheme that allows us to look at very large numbers of cells at the same time, without ever isolating a single cell," Dr. Jay Shender told the New York Times.

The team tested it using 150,000 cells from Caenorhabditis elegans (roundworm), a tiny worm that has been model for biological research since the 1960s. They not only identified the 27 known cell types, but were able to break them down into groups with mildly different gene arrangements. That includes 40 different neuron types, including a rare example that only forms one cell in very few worms.

We came up with this scheme that allows us to look at very large numbers of cells at the same time, without ever isolating a single cell.

Those results are exciting, but the system doesn't work all the time. With roundworms, for instance, it failed to identify 78 different types of previously identified neurons. "Of course, there is more to do, but I am pretty optimistic that this can be solved," said Rockefeller University's Cori Bargmann, who wasn't directly involved in the study.

The research also must be adapted to the complexities of the human body. Nevertheless, it's very promising, particularly for the Human Cell Atlas initiative being funded in part by the Chan Zuckerberg Initiative. That aims to map every cell in the human body, providing a baseline to compare healthy cells with diseased ones.

The study could reveal signature for pathology, better record cell-to-cell interactions and help scientists interpret genetic variants. The ultimate goal is to "discover targets for therapeutic intervention and ... drive the development of new technologies and and advanced analysis techniques." Much like with new gene sequencing techniques, it could help push medicine and treatments to a new level.

More here:
Scientists find a much faster way to classify our cells - Engadget

Bio-inspired Materials Give Boost to Regenerative Medicine – Bioscience Technology

What if one day, we could teach our bodies to self-heal like a lizards tail, and make severe injury or disease no more threatening than a paper cut?

Or heal tissues by coaxing cells to multiply, repair or replace damaged regions in loved ones whose lives have been ravaged by stroke, Alzheimers or Parkinsons disease?

Such is the vision, promise and excitement in the burgeoning field of regenerative medicine, now a major ASU initiative to boost 21st-century medical research discoveries.

ASU Biodesign Institute researcher Nick Stephanopoulos is one of several rising stars in regenerative medicine. In 2015, Stephanopoulos, along with Alex Green and Jeremy Mills, were recruited to the Biodesign Institutes Center for Molecular Design and Biomimetics (CMDB), directed by Hao Yan, a world-recognized leader in nanotechnology.

One of the things that that attracted me most to the ASU and the Biodesign CMDB was Haos vision to build a group of researchers that use biological molecules and design principles to make new materials that can mimic, and one day surpass, the most complex functions of biology, Stephanopoulos said.

I have always been fascinated by using biological building blocks like proteins, peptides and DNA to construct self-assembled structures, devices and materials, and the interdisciplinary and highly collaborative team in the CMDB is the ideal place to put this vision into practice.

Yans research center uses DNA and other basic building blocks to build their nanotechnology structures only at a scale 1,000 times smaller than the width of a human hair.

Theyve already used nanotechnology to build containers to specially deliver drugs to tissues, build robots to navigate a maze or nanowires for electronics.

To build a manufacturing industry at that tiny scale, their bricks and mortar use a colorful assortment of molecular Legos. Just combine the ingredients, and these building blocks can self-assemble in a seemingly infinite number of ways only limited by the laws of chemistry and physics and the creative imaginations of these budding nano-architects.

Learning from nature

The goal of the Center for Molecular Design and Biomimetics is to usenatures design rulesas an inspiration in advancing biomedical, energy and electronics innovation throughself-assembling moleculesto create intelligent materials for better component control and for synthesis intohigher-order systems, said Yan, who also holds the Milton Glick Chair in Chemistry and Biochemistry.

Prior to joining ASU, Stephanopoulos trained with experts in biological nanomaterials, obtaining his doctorate with the University of California Berkeleys Matthew Francis, and completed postdoctoral studies with Samuel Stupp at Northwestern University. At Northwestern, he was part of a team that developed a new category of quilt-like, self-assembling peptide and peptide-DNA biomaterials for regenerative medicine, with an emphasis in neural tissue engineering.

Weve learned from nature many of the rules behind materials that can self-assemble. Some of the most elegant complex and adaptable examples of self-assembly are found in biological systems, Stephanopoulos said.

Because they are built from the ground-up using molecules found in nature, these materials are also biocompatible and biodegradable, opening up brand-new vistas for regenerative medicine.

Stephanopoulos tool kit includes using proteins, peptides, lipids and nucleic acids like DNA that have a rich biological lexicon of self-assembly.

DNA possesses great potential for the construction of self-assembled biomaterials due to its highly programmable nature; any two strands of DNA can be coaxed to assemble to make nanoscale constructs and devices with exquisite precision and complexity, Stephanopoulos said.

Proof all in the design

During his time at Northwestern, Stephanopoulos worked on a number of projects and developed proof-of-concept technologies for spinal cord injury, bone regeneration and nanomaterials to guide stem cell differentiation.

Now, more recently, in a new studyin Nature Communications, Stephanopoulos and his colleague Ronit Freeman in the Stupp laboratory successfully demonstrated the ability to dynamically control the environment around stem cells, to guide their behavior in new and powerful ways.

In the new technology, materials are first chemically decorated with different strands of DNA, each with a unique code for a different signal to cells.

To activate signals within the cells, soluble molecules containing complementary DNA strands are coupled to short protein fragments, called peptides, and added to the material to create DNA double helices displaying the signal.

By adding a few drops of the DNA-peptide mixture, the material effectively gives a green light to stem cells to reproduce and generate more cells. In order to dynamically tune the signal presentation, the surface is exposed to a soluble single-stranded DNA molecule designed to grab the signal-containing strand of the duplex and form a new DNA double helix, displacing the old signal from the surface.

This new duplex can then be washed away, turning the signal off. To turn the signal back on, all that is needed is to now introduce a new copy of single-stranded DNA bearing a signal that will reattach to the materials surface.

One of the findings of this work is the possibility of using the synthetic material to signal neural stem cells to proliferate, then at a specific time selected by the scientist, trigger their differentiation into neurons for a while, before returning the stem cells to a proliferative state on demand.

One potential use of the new technology to manipulate cells could help cure a patient with neurodegenerative conditions like Parkinsons disease.

The patients own skin cells could be converted to stem cells using existing techniques. The new technology could help expand the newly converted stem cells back in the lab and then direct their growth into specific dopamine-producing neurons before transplantation back to the patient.

People would love to have cell therapies that utilize stem cells derived from their own bodies to regenerate tissue, Stupp said. In principle, this will eventually be possible, but one needs procedures that are effective at expanding and differentiating cells in order to do so. Our technology does that.

In the future, it might be possible to perform this process entirely within the body. The stem cells would be implanted in the clinic, encapsulated in the type of material described in the new work, and injected into a particular spot. Then the soluble peptide-DNA molecules would be given to the patient to bind to the material and manipulate the proliferation and differentiation of transplanted cells.

Scaling the barriers

One of the future challenges in this area will be to develop materials that can respond better to external stimuli and reconfigure their physical or chemical properties accordingly.

Biological systems are complex, and treating injury or disease will in many cases necessitate a material that can mimic the complex spatiotemporal dynamics of the tissues they are used to treat, Stephanopoulos said.

It is likely that hybrid systems that combine multiple chemical elements will be necessary; some components may provide structure, others biological signaling and yet others a switchable element to imbue dynamic ability to the material.

A second challenge, and opportunity, for regenerative medicine lies in creating nanostructures that can organize material across multiple length scales. Biological systems themselves are hierarchically organized: from molecules to cells to tissues, and up to entire organisms.

Consider that for all of us, life starts simple, with just a single cell. By the time we reach adulthood, every adult human body is its own universe of cells, with recent estimates of 37 trillion or so. The human brain alone has 100 billion cells or about the same number of cells as stars in the Milky Way galaxy.

But over the course of a life, or by disease, whole constellations of cells are lost due to the ravages of time or the genetic blueprints going awry.

Collaborative DNA

To overcome these obstacles, much more research funding and recruitment of additional talent to ASU will be needed to build the necessary regenerative medicine workforce.

Last year, Stephanopoulos research received a boost with funding from the U.S. Air Forces Young Investigator Research Program (YIP).

The Air Force Office of Scientific ResearchYIP award will facilitate Nicks research agenda in this direction, and is a significant recognition of his creativity and track record at the early stage of his careers, Yan said.

Theyll need this and more to meet the ultimate challenge in the development of self-assembled biomaterials and translation to clinical applications.

Buoyed by the funding, during the next research steps, Stephanopoulos wants to further expand horizons with collaborations from other ASU colleagues to take his research teams efforts one step closer to the clinic.

ASU and the Biodesign Institute also offer world-class researchers in engineering, physics and biology for collaborations, not to mention close ties with the Mayo Clinic or a number of Phoenix-area institutes so we can translate our materials to medically relevant applications, Stephanopoulos said.

There is growing recognition that regenerative medicine in the Valley could be a win-win for the area, in delivering new cures to patients and building, person by person, a brand-new medicinal manufacturing industry.

Stephanopoulos recent research was carried out at Stupps Northwesterns Simpson Querrey Institute for BioNanotechnology. The National Institute of Dental and Craniofacial Research of the National Institutes of Health (grant 5R01DE015920) provided funding for biological experiments, and the U.S. Department of Energy, Office of Science, Basic Energy Sciences provided funding for the development of the new materials (grants DE-FG01-00ER45810 and DE-SC0000989 supporting an Energy Frontiers Research Center on Bio-Inspired Energy Science (CBES)).

The paper is titled Instructing cells with programmable peptide DNA hybrids. Samuel I. Stupp is the senior author of the paper, and post-doctoral fellows Ronit Freeman and Nicholas Stephanopoulos are primary authors.

See the original post:
Bio-inspired Materials Give Boost to Regenerative Medicine - Bioscience Technology

ASC Biosciences, Inc. to appear on the "Informed" series hosted by Rob Lowe – Markets Insider

PALM DESERT, Calif., Aug. 21, 2017 /PRNewswire/ --ASC Biosciences, Inc. (formerly Nevis Capital Corporation) ("ASC") (OTC Pink Open Markets: "ASCW") is pleased to announce it will appear on the award-winning program "Informed" hosted by Rob Lowe.

Informed is an award-winning program that highlights new stories and innovated concepts through ground breaking short-form and long-form documentary presentation. The program, which is anchored by a veteran production team with decades of industry experience, is able to effectively communicate the most critical stories to a wide and diverse audience. "Informed" is hosted by the inimitable Rob Lowe.

ASC Biosciences, Inc. ("ASC" or the "Company") is a development stage biotechnology company that has a proprietary adult stem cell platform capable of forming nearly every tissue in the human body. These cells, Multipotent Adult Stem Cells ("MASCs"), will differentiate into cartilage, bone, tendon, muscle, ligament, fat, blood vessels, nerves, skin, etc. in humans. MASCs have apparent unlimited proliferation potential (do not reach replicative senescence) and have been shown to regenerate tissues by differentiating into the cell types at the site. MASCs lack the ability to cause a rejection response, and can thus be used as an allogenic transplant - which means that cells harvested from a single donor can be expanded in culture and the expanded cells can be used to treat hundreds, thousands, or millions of patients. TheMissionof ASC Biosciences is to provide surgeons around the world with our proprietary brand of unlimited allogeneic "Stem Cells in a Bottle" to be used in a wide variety of FDA Approved orthopedic and cosmetic therapies, resulting in permanent tissue regeneration; thus avoiding the repeat treatments commonly required in the current generation of approved stem cell therapies. ASC intends to establish an intellectual property portfolio that will provide proprietary dominion in the repair and regeneration of all human tissues. For more information visit:http://www.ascbio.comor @ASCbio1 on Facebook.

ASC trades on the OTC Pink Open Markets under the symbol: ASCW.

Forward-Looking StatementsCertain statements contained herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about ASC Biosciences, Inc. industry, management's beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict.

Because such statements involve risks and uncertainties, the actual results and performance of the Company may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Readers should review carefully reports or documents the Company files periodically with the OTC Markets -https://www.otcmarkets.com.

View original content:http://www.prnewswire.com/news-releases/asc-biosciences-inc-to-appear-on-the-informed-series-hosted-by-rob-lowe-300507183.html

SOURCE ASC Biosciences, Inc.

Read the original:
ASC Biosciences, Inc. to appear on the "Informed" series hosted by Rob Lowe - Markets Insider

Want to live longer? Forever Labs wants to help, using your stem cells – Digital Trends

Get today's popular DigitalTrends articles in your inbox:

Why it matters to you

Forever Labs hopes that by storing your stem cells, you can fight disease and slow aging.

We may have found the Fountain of Youth. Or at the very least, weve found Forever Labs. Its a new Y Combinator startup that seeks to help you live longer and healthier by preserving adult stem cells. Because as it turns out, drinking from a mythical source of water is not, in fact, the key to eternity.

While some of us may be familiar with the concept of freezing our eggs, few until now have considered applying the same concept to our stem cells. But this, Forever Labs believes, is a mistake. This is because stem cells can be transformed into any kind of cell the body needs (which is why so much research already exists surrounding these supremely adaptable cells). However, as Forever Labs points out on its website, The number and therapeutic quality of our stem cells diminishes with age. But if you store them, you may be able to preserve them for future use, thereby combating disease and, just maybe, aging.

How does it work? Using a patented device, Forever Labs collects stem cells from your blood marrow, which the team calls a wellspring for stem cells that replenish your blood, bone, immune system, and other vital tissues. The whole process is said to take around 15 minutes, with most clients reporting a five to 10 second pressure-like sensation. And dont worry no scars will result from the process.

Once your cells have been extracted, the company offers to grow and bank your cells for $2,500, as TechCrunch explains. Youll need to pay an extra $250 every year for storing your cells, or if youd rather, just pay a flat fee of $7,000 for life.

If youre looking to get into the storage game earlier rather than later (Forever Labs will start collecting cells as long as youre 18 or over, and suggests that younger is better), then it seems that this $7,000 option might be a bit better. As the loss and decline of bone marrow stem cells continues throughout ones life, Forever Labs notes, and as this decline accelerates with age, storing at anyage may provide benefits to your future self,

So if youre looking for a way to live forever (or just a bit longer), this may be a good way to hedge your bets.

See the rest here:
Want to live longer? Forever Labs wants to help, using your stem cells - Digital Trends

The Adult Brain Can Regenerate Neurons in an Unexpected Area, Says New Study – ScienceAlert

Scientists have discovered for the first time that adult mouse brains produce new cells in the amygdala, a finding that could eventually lead to better treatments for conditions like anxiety and depression, as well as a better understanding of the brain overall.

The amygdala handles a lot of our emotional responses, especially those relating to fear, and broken connections inside it can lead to anxiety disorders such as post-traumatic stress disorder (PTSD).

If the brain is capable of regenerating neurons in the amygdala, then that's potentially one way of fighting back against these mental health issues, according to the team from the University of Queensland in Australia.

"While it was previously known that new neurons are produced in the adult brain, excitingly this is the first time that new cells have been discovered in the amygdala," says one of the team, Pankaj Sah from the Queensland Brain Institute.

"Our discovery has enormous implications for understanding the amygdala's role in regulating fear and fearful memories."

Before now, neurogenesis the process of producing new neurons had only been spotted in human adults in the hippocampus, the part of the brain that handles long-term memory and also deals with emotional responses, and the striatum.

Adult neurogenesis was first recognised in the 1960s, but was more widely accepted in the 1990s, thanks in part to the discovery of stem cells in adult mice brains cells that can divide and develop into other types of cells.

That discovery was made by another team from the Queensland Brain Institute, and since then, scientists have confirmed the same process happens in humans.

Now it looks like it's happening elsewhere too: based on new studies of mice, the researchers found evidence for the same stem cells in the amygdala, cells that could turn into genuine, fully functioning neurons. Now the task is to find the same results in humans.

Right now it's not clear what those new neurons do, or how the brain uses them, but their location is interesting and worthy of further study.

There's so much we still don't know about the brain, though its secrets are slowly being unlocked. As far as neurogenesis goes, for example, we know that a session on the booze slows down the process, though giving up the drink reverses the process.

Meanwhile, a study published in July found that implanting stem cells into the brain can help to extend the lifespan of mice, and it's possible that a similar approach here could also have a positive effect.

"Finding ways of stimulating the production of new brain cells in the amygdala could give us new avenues for treating disorders of fear processing, which include anxiety, PTSD and depression," says one of the team, Dhanisha Jhaveri.

The research has been published in Molecular Psychiatry.

See the original post here:
The Adult Brain Can Regenerate Neurons in an Unexpected Area, Says New Study - ScienceAlert

The Vital Role of Emerging Gene Transfer Methods in T-cell Cancer Therapy – Bioscience Technology

Alternatively, non-viral transfection of DNA plasmids via advanced electroporation techniques, as well as liposomal formulation, nanoparticles, and cell-penetrating peptides, are increasingly being adopted due to their low immunogenicity and low risk of insertional mutagenesis. In particular, non-viral electroporation methods offer further advantages over viral methods, such as being more cost-effective and allowing the delivery of larger gene inserts. Early results suggest CAR T-cells generated by non-viral electroporation methods are effective in treating certain types of cancer (e.g. Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to tyrosine kinase inhibitors). Therefore, all this indicates that non-viral transfection via electroporation is likely to become one of the preferred methods over viral-mediated transduction for engineering CAR T-cells in the future.

Although non-viral bioprocessing methods have great potential over viral methods in terms of their clinical application in human cancer therapy, they present some limitations that need to be overcome before they can be adopted for routine clinical use. Specifically, it has been difficult to validate non-viral methods in human applications, mainly because of the low efficiency of gene transfer they provide and subsequent insufficient integration into the immune system. Yet, enhanced electroporation techniques combined with DNA transposition methods have started to show great promise in resolving these challenges, thus providing fresh impetus for their application in human cancer therapy.

DNA transposition has emerged as a non-viral gene insertion method to generate CAR T-cells. In DNA transposition, transposons (defined segments of DNA) move from one genomic location to another facilitated by one or more proteins, called the transposase. Transposons have been unveiled as a simple, yet powerful, genetic editing tool for mutagenesis (that is, to remove and/or integrate genetic sequences ex vivo) in vertebrates. Transposon-transposase systems have been shown to successfully transfer CAR transgene cassettes into T-cells to produce CAR T-cells for safe, inexpensive, and effective therapeutic purposes, such as the fish-derived Sleeping Beauty (SB) and insect-derived piggyBac human-adapted transposition systems.

Advanced electroporation technologies have transformed the capability of these transposition systems in the non-viral generation of CAR T-cells. Such systems provide highly effective methods for genetically modifying T-cells, amongst other cell types, and can be ideal for more complex transfection scenarios where multiple or even different substrate types need to be co-delivered (for example, CAR T-cell generation). Systems are available that even enable closed transfection to be performed for up to 1x109 cells, allowing for large-scale generation of CAR T-cells for immunotherapy development. These technologies can improve the efficiency of non-viral gene transfer, and so enhance the safe and effective integration of CAR T-cells into a patients immune system.

Given that non-viral transposition is still at an early stage in its clinical application, enhanced approaches to using it are still being investigated to potentially heighten the availability of safe, low cost, and efficient CAR T-cell cancer therapy in routine clinical use. For example, SB transposition of CAR genes from minimalistic DNA vectors called minicircles (MCs) have been found to produce a higher proportion of non-toxic MC-derived CAR transposons compared to those produced by viral methods.

As well as non-viral transposition systems, other new methods have shown promise in reducing the unwanted off-tissue toxicity that can be produced by genetically modified T-cells. By using transiently expressed mRNAs, CAR expression can be switched on or off to limit on-target, off-tissue toxicity to normal tissue. Yet, this technique cannot provide the long-term expression needed for maximal CAR T-cell function and sustained defense against cancer, so requires further investigation.

More recently, CRISPR/Cas9 has been used to introduce CAR sequences into T-cells. Targeted integration of CAR sequences into the TCR locus has allowed for endogenous control of CAR expression with parallel knockout of the TCR, which may generate a more effective and safer CAR T-cell population. CRISPR/Cas9 has also been used to knockout the inhibitory checkpoint PD-1 receptor in T-cells to potentially improve the efficiency of T-cell based therapeutics. These studies highlight the potential of CRISPR/Cas9 genome editing to advance the efficiency, safety, and effectiveness of immunotherapies.

CAR T-cell immunotherapies are becoming increasingly important in treating cancer, especially as non-viral gene modification technologies become more advanced and our understanding of immunology improves. The next challenge is to address how best to ensure robust and sustained CAR T-cell activity, and obtain the required anti-tumor effects without producing off-target toxicity, to improve patient outcomes.

The future of T-cell cancer therapy is likely to involve precision treatments that target the specific molecular mechanisms underpinning cancer in individual patients or groups of patients. This may also combine CAR T-cell therapy with other treatments (e.g. vaccines, checkpoint blockade drugs) to complement each of their respective limitations. Ultimately, manufacturing processes might be able to consistently produce T-cell therapies to the desired specification through automated engineering, or they might become available from a scalable allogeneic off the shelf universal source.

As cancer incidence worldwide continues to rise at an alarming rate, the race to find an effective treatment has never been so important. Yet, the remarkable progress that cancer immunotherapies have made in recent years has given us fresh hope. Advancing genetic engineering approaches and new technologies are enabling us to reinforce our natural immune defenses against cancer, generating ever stronger CAR T-cell therapies to provide cancer patients with the best care possible.

Follow this link:
The Vital Role of Emerging Gene Transfer Methods in T-cell Cancer Therapy - Bioscience Technology